New Hampshire SB256: (New Title) establishing safety and care requirements for clinician-administered drugs.

Sponsors

• Tim McGough (R, 11) · primary sponsor
• William Gannon (R, 23)
• David Rochefort (R, 1)
• John Potucek (R, 13)
• Julie Miles (R, 12)

Latest actions

1. May 14, 2026: Refer for Interim Study: MA VV 05/14/2026 HJ 13
2. May 1, 2026: Committee Report: Refer for Interim Study 04/29/2026 (Vote 15-0; CC) HC 19 P. 6
3. April 22, 2026: Executive Session: 04/29/2026 10:00 am GP 229
4. April 16, 2026: Subcommittee Work Session: 04/22/2026 10:00 am GP 229
5. April 2, 2026: Public Hearing: 04/07/2026 02:15 pm GP 159
6. April 1, 2026: Subcommittee Work Session: 04/08/2026 10:00 am GP 229
7. March 2, 2026: Vacated and Referred to Commerce and Consumer Affairs (Rep. Kofalt): MA VV (in recess of) 02/19/2026 HJ 5 P. 127
8. February 26, 2026: Introduced (in recess of) 02/19/2026 and referred to Health, Human Services and Elderly Affairs HJ 5 P. 124
9. January 7, 2026: Ought to Pass with Amendment #2025-3029s, MA, VV; OT3rdg; 01/07/2026; SJ 1
10. January 7, 2026: Committee Amendment # 2025-3029s, AA, VV; 01/07/2026; SJ 1

Common questions

What is SB256?

SB256 is a bill in the New Hampshire Legislature (2025 Regular Session): (New Title) establishing safety and care requirements for clinician-administered drugs.

What is the status of SB256?

In committee as of May 14, 2026. Latest action: Refer for Interim Study: MA VV 05/14/2026 HJ 13 (May 14, 2026).

Who sponsored SB256?

Tim McGough (R, 11), with 4 co-sponsors.

Where is the official record for SB256?

On the New Hampshire Legislature website: https://gc.nh.gov/bill_status/legacy/bs2016/bill_docket_report.aspx?lsr=1003&sy=2026